Niraparib (trade name in Hong Kong: Zele) is a highly effective and selective once-daily oral small molecule poly(ADP-ribose) PARP1/2 inhibitor for late-stage recurrent ovarian cancer. Maintenance therapy can significantly extend the survival period of patients with advanced ovarian cancer and reduce the recurrence of ovarian cancer.
Let us work together to protect precious health